NOV 23, 2015 7:00 AM PST

WEBINAR: New specificities in the antiphospholipid syndrome: The importance of testing for aPS/PT and anti-β2 Domain 1 antibodies (Spanish Language)

Speaker
  • Managing Editor of the journal Lupus, Chairman of the Antiphospholipid Syndrome Laboratory Diagnostics and Trends Task Force, Executive Committee Member of the APS alliance for clinical tri
    Biography
      Dr Maria Laura Bertolaccini was born in Rosario, Argentina where she graduated from the Medical School at the National University of Rosario. Shejoined the Lupus Unit in 1996 as a Clinical Research Fellow. In 2004, she was awarded her PhD degree by King's College London. Dr Bertolaccini is the Managing Editor of Lupus an international journal. She is the Co-Chair of the Standardisation subcommittee on Lupus anticoagulant and antiphospholipid antibodies at the International Society for Thrombosis and Haemostasis (ISTH), Chairman of the Antiphospholipid Syndrome Laboratory Diagnostics and Trends Task Force andE xecutive Committee Member of the Antiphospholipid syndrome alliance for clinical trials and international networking (APS Action). Dr Bertolaccini has published 84 peer-review papers, 2 books, 11 book chapters and presented more than 85 abstracts at national/international meetings.

    Abstract
    Presence of anti-PS/PT IgG or IgM antibodies indicates a high risk category of patients

    Antiphospholipid antibodies are not directed against phospholipids, but rather to phospholipid-protein complexes.  Recent evidence suggests that antibodies to the complex of PS and PT (PS/PT) identifies a distinct subset of patients with very high likelihood of adverse events. Antibodies targeted to either PS or PT yield less clinically relevant information as antibodies towards the PS/PT complex.

    Recent studies have shown that the risk of thrombotic events increases with the number of positive test results in APS patients and aPL carriers. Triple positivity for LAC, anti-β2GP1, and PS/PT demonstrated the highest diagnostic accuracy out of 23 possible combinations of aPL tests.

    Inclusion of PS/PT testing into routine testing can improve patient outcome.

    Anti-β2GP1 domain 1 antibodies are highly specific for the diagnosis of APS and may help support therapeutic decision making

    Anti-β2GP1 antibodies target multiple epitopes in the same molecule. A growing body of evidence indicates that domain 1 is the most relevant epitope targeted by anti-β2GP1 antibodies in patients with APS. Many studies have shown that anti-domain 1 antibodies identify a distinct population of patients with a high risk of thromboembolic events, despite therapy.  In addition, carriers are high risk to develop a first thromboembolic event.
     

    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    APR 20, 2021 11:00 AM PDT
    C.E. CREDITS
    APR 20, 2021 11:00 AM PDT
    Date: April 20, 2021 Time: 11:00am (PST), 2:00pm (EST) Identification and confirmation of microbial isolates is crucial in the analysis workflow, providing decision-makers the information...
    DEC 03, 2020 9:00 AM PST
    C.E. CREDITS
    DEC 03, 2020 9:00 AM PST
    Date: December 3, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Scientific cameras used in applications such as light sheet microscopy and calcium/voltage imaging put a large emphasis on high speed...
    APR 19, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 19, 2021 8:00 AM PDT
    Date: Apri 19, 2021 Time: 8:00am PDT, 5:00pm CEST Since the inception of modern biological research, BioSafety has evolved into a critical consideration in Good Laboratory Practices (GLP). Wi...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    MAR 18, 2021 8:00 AM PDT
    C.E. CREDITS
    MAR 18, 2021 8:00 AM PDT
    DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
    Loading Comments...
    Show Resources
    Attendees
    • See more